{
    "claims": [
        {
            "claim_id": "C01",
            "claim": "Intratumoral mRNA vaccination sensitizes tumors to immune checkpoint blockade.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade",
                    "line_ref": "L4"
                },
                {
                    "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
                    "line_ref": "L46"
                }
            ],
            "caveat": "The study supports a biologically coherent hypothesis, but prospective randomized studies are required before clinical protocol changes are justified."
        },
        {
            "claim_id": "C02",
            "claim": "mRNA vaccination broadens the displayed antigen landscape in tumors.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
                    "line_ref": "L28"
                },
                {
                    "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
                    "line_ref": "L29"
                }
            ],
            "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
        },
        {
            "claim_id": "C03",
            "claim": "The sensitization effect is mediated by type I interferon signaling.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
                    "line_ref": "L39"
                },
                {
                    "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
                    "line_ref": "L42"
                }
            ],
            "caveat": "Mouse model effects may not map one-to-one to all human tumors."
        },
        {
            "claim_id": "C04",
            "claim": "Prior mRNA vaccination is associated with improved survival in human patients receiving ICI.",
            "strength": "moderate",
            "evidence": [
                {
                    "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
                    "line_ref": "L30"
                },
                {
                    "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
                    "line_ref": "L46"
                }
            ],
            "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
        }
    ]
}